SangStat regulatory update

SANG today was to announce that it has received European Patent No. 510949 covering its Xenoject platform technology for developing drugs that provoke the immune system to reject undesirable cells, such as infected or cancerous cells.

Read the full 365 word article

How to gain access

Continue reading with a
two-week free trial.